Study Of Prevention of Chemo-Induced Nausea and Vomiting Caused By Moderately Emetogenic Chemotherapy
Public ClinicalTrials.gov record NCT00104403. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging, Parallel Group Study of the Safety and Efficacy of the Oral NeuroKinin-1 Receptor Antagonist, GW679769 in Combination With Ondansetron Hydrochloride and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study was designed to assess the safety and efficacy of different dosages and administration schedules of an investigational agent administered over 3 days when added to standard therapy used in the prevention of chemotherapy-induced nausea and vomiting in cancer patients. Subjects will be asked to complete daily diaries while on study medication. In addition subjects will be required to return to the investigational site several times during the course of the study for follow up safety assessments which may include blood samples for hematology and chemistry evaluations as well as physical exams. A final assessment will be preformed on study Day 20-30 at which time the subject will complete the study.
Study identification
- NCT ID
- NCT00104403
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 722 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 2004 (Type not available)
- Primary completion
- Jan 2006 (Actual)
- Completion
- Jan 2006 (Actual)
- Last update posted
- Apr 16, 2015
2004 – 2006
United States locations
- U.S. sites
- 47
- U.S. states
- 24
- U.S. cities
- 46
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Birmingham | Alabama | 35209 | — |
| GSK Investigational Site | Corona | California | 92882 | — |
| GSK Investigational Site | Greenbrae | California | 94904-2007 | — |
| GSK Investigational Site | Loma Linda | California | 92354 | — |
| GSK Investigational Site | Los Angeles | California | 90057 | — |
| GSK Investigational Site | Palm Springs | California | 92262 | — |
| GSK Investigational Site | Lakewood | Colorado | 80215 | — |
| GSK Investigational Site | Boynton Beach | Florida | 33435 | — |
| GSK Investigational Site | Hudson | Florida | 34667 | — |
| GSK Investigational Site | Miami | Florida | 33138 | — |
| GSK Investigational Site | Ocala | Florida | 34474 | — |
| GSK Investigational Site | Centralia | Illinois | 62801 | — |
| GSK Investigational Site | Park Ridge | Illinois | 60068 | — |
| GSK Investigational Site | Skokie | Illinois | 60076 | — |
| GSK Investigational Site | Evansville | Indiana | 47713 | — |
| GSK Investigational Site | Muncie | Indiana | 47303 | — |
| GSK Investigational Site | New Albany | Indiana | 47150 | — |
| GSK Investigational Site | Hutchinson | Kansas | 67502 | — |
| GSK Investigational Site | Alexandria | Louisiana | 71301 | — |
| GSK Investigational Site | Baton Rouge | Louisiana | 70809 | — |
| GSK Investigational Site | Bethesda | Maryland | 20817 | — |
| GSK Investigational Site | Worcester | Massachusetts | 01608 | — |
| GSK Investigational Site | Bay City | Michigan | 48708 | — |
| GSK Investigational Site | Tupelo | Mississippi | 38801 | — |
| GSK Investigational Site | Jefferson City | Missouri | 65109 | — |
| GSK Investigational Site | Rolla | Missouri | 65401 | — |
| GSK Investigational Site | St Louis | Missouri | 63141 | — |
| GSK Investigational Site | Sparta | New Jersey | 07871 | — |
| GSK Investigational Site | Rochester | New York | 14621 | — |
| GSK Investigational Site | The Bronx | New York | 10467-2490 | — |
| GSK Investigational Site | Bismarck | North Dakota | 58503 | — |
| GSK Investigational Site | Akron | Ohio | 44304 | — |
| GSK Investigational Site | Canton | Ohio | 44718 | — |
| GSK Investigational Site | Sumter | South Carolina | 29150 | — |
| GSK Investigational Site | Corpus Christi | Texas | 78463-3069 | — |
| GSK Investigational Site | Dallas | Texas | 75237 | — |
| GSK Investigational Site | Houston | Texas | 77024 | — |
| GSK Investigational Site | Tyler | Texas | 75708 | — |
| GSK Investigational Site | Ogden | Utah | 84403 | — |
| GSK Investigational Site | West Point | Utah | 84341 | — |
| GSK Investigational Site | Burlington | Vermont | 05401 | — |
| GSK Investigational Site | Abingdon | Virginia | 24211 | — |
| GSK Investigational Site | Richmond | Virginia | 23230 | — |
| GSK Investigational Site | Everett | Washington | 98201 | — |
| GSK Investigational Site | Tacoma | Washington | 98405 | — |
| GSK Investigational Site | Tacoma | Washington | 98431 | — |
| GSK Investigational Site | Rhinelander | Wisconsin | 54501 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 66 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00104403, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 16, 2015 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00104403 live on ClinicalTrials.gov.